Annual Total Liabilities
$17.96 M
+$9.40 M+109.89%
December 31, 2023
Summary
- As of March 13, 2025, AVTE annual total liabilities is $17.96 million, with the most recent change of +$9.40 million (+109.89%) on December 31, 2023.
- During the last 3 years, AVTE annual total liabilities has fallen by -$97.00 thousand (-0.54%).
- AVTE annual total liabilities is now -0.54% below its all-time high of $18.06 million, reached on December 31, 2020.
Performance
AVTE Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$10.47 M
-$6.83 M-39.49%
September 30, 2024
Summary
- As of March 13, 2025, AVTE quarterly total liabilities is $10.47 million, with the most recent change of -$6.83 million (-39.49%) on September 30, 2024.
- Over the past year, AVTE quarterly total liabilities has dropped by -$7.50 million (-41.73%).
- AVTE quarterly total liabilities is now -87.54% below its all-time high of $84.01 million, reached on June 30, 2021.
Performance
AVTE Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
AVTE Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +109.9% | -41.7% |
| 3 y3 years | -0.5% | -41.7% |
| 5 y5 years | +151.0% | -41.7% |
AVTE Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +509.9% | -41.7% | +255.4% |
| 5 y | 5-year | -0.5% | +509.9% | -87.5% | +255.4% |
| alltime | all time | -0.5% | +509.9% | -87.5% | +255.4% |
Aerovate Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $10.47 M(-39.5%) |
| Jun 2024 | - | $17.30 M(+8.7%) |
| Mar 2024 | - | $15.92 M(-11.4%) |
| Dec 2023 | $17.96 M(+109.9%) | $17.96 M(+18.5%) |
| Sep 2023 | - | $15.15 M(+9.6%) |
| Jun 2023 | - | $13.83 M(+22.4%) |
| Mar 2023 | - | $11.30 M(+32.0%) |
| Dec 2022 | $8.56 M | $8.56 M(+0.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $8.52 M(+83.9%) |
| Jun 2022 | - | $4.63 M(-8.3%) |
| Mar 2022 | - | $5.05 M(+71.5%) |
| Dec 2021 | $2.94 M(-83.7%) | $2.94 M(-31.1%) |
| Sep 2021 | - | $4.28 M(-94.9%) |
| Jun 2021 | - | $84.01 M(+222.3%) |
| Mar 2021 | - | $26.06 M(+44.3%) |
| Dec 2020 | $18.06 M(+152.3%) | $18.06 M |
| Dec 2019 | $7.16 M | - |
FAQ
- What is Aerovate Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Aerovate Therapeutics?
- What is Aerovate Therapeutics annual total liabilities year-on-year change?
- What is Aerovate Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Aerovate Therapeutics?
- What is Aerovate Therapeutics quarterly total liabilities year-on-year change?
What is Aerovate Therapeutics annual total liabilities?
The current annual total liabilities of AVTE is $17.96 M
What is the all time high annual total liabilities for Aerovate Therapeutics?
Aerovate Therapeutics all-time high annual total liabilities is $18.06 M
What is Aerovate Therapeutics annual total liabilities year-on-year change?
Over the past year, AVTE annual total liabilities has changed by +$9.40 M (+109.89%)
What is Aerovate Therapeutics quarterly total liabilities?
The current quarterly total liabilities of AVTE is $10.47 M
What is the all time high quarterly total liabilities for Aerovate Therapeutics?
Aerovate Therapeutics all-time high quarterly total liabilities is $84.01 M
What is Aerovate Therapeutics quarterly total liabilities year-on-year change?
Over the past year, AVTE quarterly total liabilities has changed by -$7.50 M (-41.73%)